The dual regulatory role of PKM2 may perturb immunometabolic homeostasis; the fluctuating nutrient landscape of the tumor microenvironment can drive adaptive resistance; and some inhibitors exhibit limited specificity or unacceptable toxicity. The gene discussed is PKM; the disease is neoplasm.